Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II
Emmanuel J. Favaloro, Giuseppe Lippi
Abstract
Welcome to another issue of Seminars in Thrombosis and Hemostasis (STH). This issue is published under the "banner" of "Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) : Part II"; this being the second such issue. The first issue was published in 2020 and has proved very popular with the STH readership.[1] [2] COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Believed to originate from Wuhan City in China, with the first reported case in December 2019, at time of writing, there were over 113 million cases reported worldwide, and over 2.5 million attributable deaths.[3] This compares to 26 million cases reported worldwide, and nearly 900,000 attributable deaths, at the time of writing the first COVID-19 issue Preface (August 30, 2020).[1] From a smattering of reports in the scientific literature in late 2019 (n = 228), there are now over 100,000 publications ascribed to COVID-19 in PubMed, including almost 12,000 reviews. This compares to 51,000 publications, including over 5,000 reviews, at the time of writing the first COVID-19 issue Preface.[1] Thus, cases of COVID-19 have continued to grow at a fast pace, deaths attributable to it have tripled, and publications doubled since the first issue Preface, a short half year ago.[1] As this intriguing virus continues to mutate, evolves, and attempts to adapt to the host (i.e., us), this may continue to be the state of play, at least for the immediate future.